Tumor-Targeting Polymer-Drug Conjugate for Liver Cancer Treatment In Vitro

Polymers (Basel). 2022 Oct 25;14(21):4515. doi: 10.3390/polym14214515.

Abstract

Bufalin (buf) has poor solubility in aqueous solution, poor tumor targeting, and many non-specific toxic and side effects. The advantages of high-molecular-weight polymer conjugates are that they can improve the water solubility of buf, prolong plasma half-life, and reduce non-specific toxicity. A novel water-soluble polymer-drug conjugate with buf and fluorescein pendants was prepared by the combination of reversible addition-fragmentation transfer (RAFT) polymerization and click chemistry. Its anticancer performance and cellular uptake behavior against liver cancer were investigated in vitro. The polymer-buf conjugates exhibit controlled release and tumor-targeting capabilities, showing promise for clinical applications.

Keywords: bufalin; esterase responsive; liver cancer; polymer–drug conjugate.